Giulia Falconi

List of Publications by Year
in descending order

32 papers	440 citations	686830 13 h-index	794141 19 g-index
35 all docs	35 docs citations	35 times ranked	769 citing authors

#	Article	IF	Citations
1	Clonal haematopoiesis as a risk factor for therapyâ€related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemoâ€(immuno)therapy. British Journal of Haematology, 2022, 198, 103-113.	1.2	7
2	Atypical Rearrangements in APL-Like Acute Myeloid Leukemias: Molecular Characterization and Prognosis. Frontiers in Oncology, 2022, 12, 871590.	1.3	16
3	In vitro effect of eltrombopag alone and in combination with azacitidine on megakaryopoiesis in patients with myelodysplastic syndrome. Platelets, 2021, 32, 378-382.	1.1	2
4	From Clonal Hematopoiesis to Therapy-Related Myeloid Neoplasms: The Silent Way of Cancer Progression. Biology, 2021, 10, 128.	1.3	5
5	Whatâ€™s new in the pathogenesis and treatment of therapy-related myeloid neoplasms. Blood, 2021, 138, 749-757.	0.6	23
6	Mutational profile of ZBTB16â€RARAâ€positive acute myeloid leukemia. Cancer Medicine, 2021, 10, 3839-3847.	1.3	9
7	WT1 evaluation in higher-risk myelodysplastic syndrome patients treated with azacitidine. Leukemia and Lymphoma, 2020, 61, 979-982.	0.6	1
8	Clonal Hematopoiesis Is Associated with Increased Risk for Therapy-Related Myeloid Neoplasms in Chronic Lymphocytic Leukemia Patients Treated with Chemo(immuno)Therapy. Blood, 2020, 136, 19-20.	0.6	1
9	Mutational landscape of patients with acute promyelocytic leukemia at diagnosis and relapse. American Journal of Hematology, 2019, 94, 1091-1097.	2.0	25
10	Cytotoxicity and Differentiating Effect of the Poly(ADP-Ribose) Polymerase Inhibitor Olaparib in Myelodysplastic Syndromes. Cancers, 2019, 11, 1373.	1.7	13
11	Transcription factors implicated in late megakaryopoiesis as markers of outcome after azacitidine and allogeneic stem cell transplantation in myelodysplastic syndrome. Leukemia Research, 2019, 84, 106191.	0.4	5
12	The Role of Forkhead Box Proteins in Acute Myeloid Leukemia. Cancers, 2019, 11, 865.	1.7	22
13	Genetic analysis of erythrocytosis reveals possible causative and modifier gene mutations. British Journal of Haematology, 2019, 186, e100-e103.	1.2	2
14	Mutational profile and haematological response to iron chelation in myelodysplastic syndromes (<scp>MDS</scp>). British Journal of Haematology, 2019, 185, 954-957.	1.2	4
15	Early and sensitive detection of PML-A216V mutation by droplet digital PCR in ATO-resistant acute promyelocytic leukemia. Leukemia, 2019, 33, 1527-1530.	3.3	16
16	Somatic mutations as markers of outcome after azacitidine and allogeneic stem cell transplantation in higher-risk myelodysplastic syndromes. Leukemia, 2019, 33, 785-790.	3.3	33
17	Longitudinal detection of DNMT3A^{R882H} transcripts in patients with acute myeloid leukemia. American Journal of Hematology, 2018, 93, E120-E123.	2.0	7
18	Therapy-related myeloid neoplasms: clinical perspectives. OncoTargets and Therapy, 2018, Volume 11, 5909-5915.	1.0	12

#	Article	IF	Citations
19	Erythropoietin levels and erythroid differentiation parameters in patients with lower-risk myelodysplastic syndromes. Leukemia Research, 2018, 71, 89-91.	0.4	2
20	Unravelling Genetic Mechanisms of Erythrocytosis: A Real-Life Experience from a Single Center. Blood, 2018, 132, 3617-3617.	0.6	0
21	Expression Profile of Bone Marrow Mesenchymal Stromal Cells Isolated from Patients with Therapy-Related Myeloid Neoplasms. Leukemia Research, 2017, 55, S116-S117.	0.4	1
22	Identification of i(X)(p10) as the sole molecular abnormality in atypical chronic myeloid leukemia evolved into acute myeloid leukemia. Molecular and Clinical Oncology, 2017, 8, 463-465.	0.4	4
23	The forkhead box C1 (FOXC1) transcription factor is downregulated in acute promyelocytic leukemia. Oncotarget, 2017, 8, 84074-84085.	0.8	4
24	Clonal evolution in therapy-related neoplasms. Oncotarget, 2017, 8, 12031-12040.	0.8	22
25	Impairment of PI3K/AKT and WNT/Î²-catenin pathways in bone marrow mesenchymal stem cells isolated from patients with myelodysplastic syndromes. Experimental Hematology, 2016, 44, 75-83.e4.	0.2	42
26	Fanconi anemia gene variants in therapy-related myeloid neoplasms. Blood Cancer Journal, 2015, 5, e323-e323.	2.8	32
27	Methylenetetrahydrofolate reductase polymorphisms in myelodysplastic syndromes and therapy-related myeloid neoplasms. Leukemia and Lymphoma, 2014, 55, 2942-2944.	0.6	4
28	TheBCL2L10Leu21Arg variant and risk of therapy-related myeloid neoplasms andde novomyelodysplastic syndromes. Leukemia and Lymphoma, 2014, 55, 1538-1543.	0.6	22
29	Why methylation is not a marker predictive of response to hypomethylating agents. Haematologica, 2014, 99, 613-619.	1.7	61
30	Mutational analysis of bone marrow mesenchymal stromal cells in myeloid malignancies. Experimental Hematology, 2014, 42, 731-733.	0.2	4
31	SETBP1 mutations in 106 patients with therapy-related myeloid neoplasms. Haematologica, 2014, 99, e152-e153.	1.7	16
32	Mutations of epigenetic regulators and of the spliceosome machinery in therapy-related myeloid neoplasms and in acute leukemias evolved from chronic myeloproliferative diseases. Leukemia, 2013, 27, 982-985.	3.3	22